CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in the 2^nd half of 2024 -

- IND application filed for conditionally activated EpCAM-directed ADC (CX-2051) with Phase 1 initiation in EpCAM positive tumors expected in the 1^st half of 2024 -

- IND application filed for conditionally activated interferon alpha-2b (CX-801) with Phase 1 initiation as monotherapy and in combination with PD-(L)1 anticipated in the 1^st half of 2024 -

- Broad pipeline progress anticipated within research and development partnerships including ongoing Phase 2 clinical trial of anti-CTLA-4 Probody BMS-986288 -

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced its 2024 company priorities and anticipated milestones for its wholly-owned and partnered pipeline.

“With INDs recently filed for wholly-owned programs, CX-2051 and CX-801, and continued progress in dose escalation with our Probody T-Cell engager, CX-904, CytomX is well positioned as we enter 2024. Our current lead programs build on more than a decade of Probody platform experience at CytomX and integrate key design elements that leverage previously validated oncology targets, potent effector mechanisms and tailored masking strategies,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. “We believe our multi-modality Probody therapeutic pipeline will address major unmet medical needs in the treatment of cancer. CytomX is entering a potentially milestone-rich period in 2024 and 2025 during which we aim to generate proof of concept clinical data across our lead programs that point the way to future registrational studies.”  

“CytomX’s multi-modality pipeline is highly relevant at this moment in time in oncology R&D. CX-904 is a potentially differentiated EGFR-CD3 T-cell engager in an ongoing Phase 1 clinical trial and, with both CX-2051 and CX-801 also expected to enter the clinic in 2024, we have a broad opportunity to make a meaningful difference in the treatment of cancer,” said Wayne Chu, M.D., chief medical officer of CytomX Therapeutics. Continued Dr. Chu, “CX-2051 is an ADC designed to truly unlock EpCAM as an anti-cancer target and we believe the topoisomerase-1 inhibitor payload may be an ideal effector mechanism for multiple EpCAM expressing tumors. CX-801 is a powerful immune-stimulating agent with potential to mitigate historical clinical limitations of cytokine therapies due to toxicity. Our vision is for CX-801 to become a cornerstone of combination regimens for a wide range of tumor types including those that have either stopped responding to, or have failed to respond to, prior immunotherapy. CytomX’s lead therapeutic candidates have the potential for significant impact and we will be working tirelessly to bring these therapies forward for the benefit of patients.”